FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Xanthic Biopharma Inc.** (the “Issuer”).

Trading Symbol: **XTHC**

Number of Outstanding Listed Securities: **57,546,547**

Date: **August 2, 2018**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Company announced on July 17, 2018 that it and Green Growth Brands Ltd. ("GGB") they have entered into an arm's length business combination agreement (the "Definitive Agreement") dated July 13, 2018 to combine Xanthic and GGB by way of amalgamation (the "Amalgamation") between GGB and a wholly-owned subsidiary of Xanthic ("Subco") to form one company as a wholly-owned subsidiary of Xanthic (the "Business Combination")that it entered was being acquired and amalgamating with Green Growth Brands. See press release dated July 17, 2018 for full explanation of the transaction.**

1. Provide a general overview and discussion of the activities of management. **N/A**
2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**No new product or service developments**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned. **N/A**
2. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**On July 3, 2018, the Company announced it was terminating the letter of intent with ABH Pharma Inc. regarding distribution of the Company’s products due to the parties’ inability to reach agreement on key business terms.**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**On July 3, 2018, the Company announced that it had terminated the letter of intent due to the parties’ inability to reach agreement on key business terms.**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship. **N/A**
2. Describe the acquisition of new customers or loss of customers. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. **N/A**
3. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. **N/A**
5. Report on any labour disputes and resolutions of those disputes if applicable. **N/A**
6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**N/A**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. **N/A**
2. Provide details of any securities issued and options or warrants granted.

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds(1)** |
| Common Shares | 700,000 | Stock option exercise | General working capital |
|  |  |  |  |
|  |  |  |  |

*(1) State aggregate proceeds and intended allocation of proceeds.*

1. Provide details of any loans to or by Related Persons. **N/A**
2. Provide details of any changes in directors, officers or committee members.

**In connection with the July 17, 2018 announcement regarding GGB amalgamation, three directors resigned, which include Peter Schwartz, David Lubotta, and Dr Shafik Dharamshi. The new directors subject to approval by CSE include Jean Schottenstein, Peter Horvath, Steve Stoute, and Marc Lehmann.**

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**The Company’s marijuana business involves certain risks and uncertainties that are inherent to the Company’s industry. Please refer to the “Risk Factors” section of the Listing Statement dated April 17, 2018 which is available on SEDAR at** [**www.sedar.com**](http://www.sedar.com)**.**

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 2, 2018 .

 David Bhumgara
Name of Director or Senior Officer

 "*David Bhumgara*"
Signature

 Chief Financial Officer
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of Issuer**Xanthic Biopharma Inc.** | For Month End**July 31, 2018** | Date of ReportYY/MM/D**August 2, 2018** |
| Issuer Address**77 King Street West, Suite 2905** |
| City/Province/Postal Code**Toronto, Ontario M5K 1A2** | Issuer Fax No.( ) | Issuer Telephone No.**( 416 ) 341-8033** |
| Contact Name**David Bhumgara** | Contact Position**CFO** | Contact Telephone No.**(416 ) 341-8033** |
| Contact Email Address**davidb@xanthicbiopharma.com** | Web Site Address**xanthicbio.com** |